date:Apr 26, 2012
Register. The FDA will carefully consider all relevant, substantive comments during the development of the final guidance documents.
Electronic comments should be submitted to http//www.regulations.gov. Written comments should be submitted to the Division of Dockets Management, (HFA-305), Food and Drug Administration, 5630 Fishers Lane,Room 1061, Rockville, MD 20852.